The new human coronavirus named SARS-CoV-2 is a positive-sense RNA virus for which no specific drugs are currently available. A knowledge-based analysis strongly suggests a possible repositioning of the anti-HCV direct antiviral agent (DAA) Sofosbuvir as treatment for SARS-CoV-2. Indeed, the RNA-dependent RNA-polymerases (RdRp) of the two viruses show high sequence and structural homology, supporting the likelihood of binding the Sofosbuvir molecule with similar efficiency. Such a repositioning would allow the containment of the SARS-CoV-2 pandemic and limit the progression of disease to potentially deadly COVID19.

中文翻译：

---

基于知识的抗 HCV 直接抗病毒药物 Sofosbuvir 作为 SARS-CoV-2 治疗的重新定位

新型人类冠状病毒名为SARS-CoV-2，是一种正义RNA病毒，目前尚无特效药物。基于知识的分析强烈表明，抗 HCV 直接抗病毒药物 (DAA) 索磷布韦 (Sofosbuvir) 可能重新定位为 SARS-CoV-2 的治疗方法。事实上，两种病毒的 RNA 依赖性 RNA 聚合酶 (RdRp) 显示出高度的序列和结构同源性，支持以相似效率结合索磷布韦分子的可能性。这样的重新定位将能够遏制 SARS-CoV-2 大流行，并限制疾病发展为可能致命的新冠病毒 (COVID19)。